Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 11/20 | 0.66 |
| ▸ | AXL | P30530 | 9/20 | 0.66 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.66 |
| ▸ | KDR | P35968 | 3/20 | 0.66 |
| ▸ | MERTK | Q12866 | 3/20 | 0.66 |
| ▸ | FLT1 | P17948 | 3/20 | 0.66 |
| ▸ | FLT3 | P36888 | 2/20 | 0.66 |
| ▸ | AURKA | O14965 | 1/20 | 0.66 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.66 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.66 |
| ▸ | ABL1 | P00519 | 1/20 | 0.66 |
| ▸ | EGFR | P00533 | 1/20 | 0.66 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.66 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.66 |
| ▸ | LCK | P06239 | 1/20 | 0.66 |
| ▸ | PGR | P06401 | 1/20 | 0.66 |
| ▸ | LYN | P07948 | 1/20 | 0.66 |
| ▸ | RET | P07949 | 1/20 | 0.66 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.66 |
| ▸ | HCK | P08631 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL372017 | 1.00 | MET (0.66) | METAXLAURKBKDRMERTK | |
| Pyruvate SCHEMBL29195420 | 0.96 | MET (0.61) | METAXLAURKBKDRMERTK | |
| SCHEMBL31105630 | 0.94 | MET (0.67) | METAXLAURKBKDRMERTK | |
| SCHEMBL28694985 | 0.94 | MET (0.62) | METAXLAURKBKDRMERTK | |
| Glutarate SCHEMBL29195414 | 0.93 | MET (0.58) | METAXLAURKBKDRMERTK | |
| SCHEMBL29453833 | 0.93 | AXL (0.57) | METAXLAURKBKDRMERTK | |
| SCHEMBL22750248 | 0.93 | AXL (0.57) | METAXLAURKBKDRMERTK | |
| SCHEMBL21201003 | 0.93 | AXL (0.57) | METAXLAURKBKDRMERTK | |
| SCHEMBL410634 | 0.92 | MET (0.58) | METAXLAURKBKDRMERTK | |
| SCHEMBL371952 | 0.92 | AURKB (0.58) | METAXLAURKBKDRMERTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036603-A | Preparation method of anti-tumor drug cabatinib | 新乡学院 | 2026-05-15 | — | — | CN | disclosed |
| US-20250333480-A1 | FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250161276-A1 | DRUG COMBINATIONS AND METHODS OF TREATING OVARIAN CANCER | Pattern Computer, Inc. | 2025-05-22 | — | — | US | disclosed |
| EP-4479047-A1 | DRUG COMBINATIONS AND METHODS OF TREATING OVARIAN CANCER | Pattern Computer, Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| CN-118984704-A | Pharmaceutical combinations and methods for treating ovarian cancer | 帕特恩电脑公司 | 2024-11-19 | — | — | CN | disclosed |
| US-20240366608-A1 | PHARMACEUTICAL COMBINATIONS OF SOS1 INHIBITORS FOR TREATING AND/OR PREVENTING CANCER | LUPIN LIMITED (IN) | 2024-11-07 | — | — | US | disclosed |
| EP-4313048-A1 | PROCESS FOR PREPARATION OF CABOZANTINIB | Biocon Limited (IN) | 2024-02-07 | — | — | EP | disclosed |
| WO-2023234222-A1 | METHOD FOR DETERMINING EFFECTIVENESS OF CANCER TREATMENT USING RET KINASE INHIBITOR | 国立研究開発法人国立がん研究センター | 2023-12-07 | — | — | WO | disclosed |
| CN-113164480-B | Pharmaceutical composition for treating diffuse gastric cancer | 学校法人金泽医科大学 | 2023-11-28 | — | — | CN | disclosed |
| WO-2023222946-A1 | PROCESS FOR THE PREPARATION OF CABOZANTINIB | FERMION OY (FI) | 2023-11-23 | — | — | WO | disclosed |
| CN-116723843-A | Pharmaceutical combination of SOS1 inhibitors for the treatment and/or prevention of cancer | 鲁宾有限公司 | 2023-09-08 | — | — | CN | disclosed |
| WO-2023159184-A1 | DRUG COMBINATIONS AND METHODS OF TREATING OVARIAN CANCER | Pattern Computer, Inc. (US) | 2023-08-24 | — | — | WO | disclosed |
| WO-2022201079-A1 | PROCESS FOR PREPARATION OF CABOZANTINIB | BIOCON LIMITED (IN) | 2022-09-29 | — | — | WO | disclosed |
| WO-2022182982-A1 | METHODS FOR TREATING C-KIT KINASE MEDIATED DISEASES AND DISORDERS USING A SELECTIVE C-KIT KINASE INHIBITOR | THIRD HARMONIC BIO, INC. (US) | 2022-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250161276-A1 | DRUG COMBINATIONS AND METHODS OF TREATING OVARIAN CANCER | TP53, TOP2A, BRCA1 | MET 79/4885AXL 2912/4885AURKB 267/4885 |
| US-20240366608-A1 | PHARMACEUTICAL COMBINATIONS OF SOS1 INHIBITORS FOR TREATING AND/OR PREVENTING CANCER | NRAS, KRAS, PRMT1 | MET 48/4885AXL 449/4885AURKB 1401/4885 |
| US-20250333480-A1 | FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | MET 714/4885AXL 909/4885AURKB 1445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.